Enhancement of rotational behavior induced by repeated administration of SKF38393 in rats with unilateral nigrostriatal 6-OHDA lesions.
To clarify if the enhancement of rotational behavior induced by repeated administration of SKF38393 is mediated by upregulation of D1 and/or D2 receptors in the striatum, we investigated effects of SCH23390 and sulpiride on SKF38393-induced rotational behavior and the changes in striatal dopamine receptors in rats with unilateral nigrostriatal 6-hydroxydopamine lesions (1). Repeated weekly administration of SKF38393 markedly enhanced the number of rotations and shortened the latency of rotational behavior depending on the number of SKF38393 administrations 1 or 6 weeks after the treatment with 6-OHDA (2). A selective D1 antagonist, SCH23390, but not a selective D2 antagonist, sulpiride, suppressed SKF38393-induced rotation and inhibited the enhancement by the repeated administration (3). Repeated administration of SKF38393 did not modify the density and the affinity of either the striatal D1 or D2 receptors in the striatum. These results suggest that the enhancement of SKF38393-induced rotational behavior by the repeated administration is not associated with the upregulation of striatal D1 and D2 receptors.
Matsuda
H
H
Department of Japanese Oriental (Kampo) Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan.
Hiyama
Y
Y
Terasawa
K
K
Watanabe
H
H
Matsumoto
K
K
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D003342:Corpus Striatum / Q000502:physiology*; D004298:Dopamine / Q000378:metabolism; D018492:Dopamine Antagonists; D008297:Male; D016627:Oxidopamine; D011869:Radioligand Assay; D051381:Rats; D011919:Rats, Inbred Strains; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D013378:Substantia Nigra / Q000502:physiology*; D013469:Sulpiride / Q000494:pharmacology
D018492:Dopamine Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D013469:Sulpiride; D016627:Oxidopamine; D004298:Dopamine